Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this retrospective observational study is to build and validate a "bio-anatomical" prognostic model for patients with esophageal squamous cell carcinoma (ESCC) who underwent neoadjuvant immunochemotherapy (nICT) followed by radical surgery. The main question it aims to answer is:
Can a "bio-anatomical" prognostic nomogram accurately predict overall survival and help guide individualized post-surgery treatment for ESCC patients after nICT better than traditional staging? Researchers will retrospectively analyze the clinical, pathological (including a new lymph node response indicator), and overall survival data of 414 eligible patients treated across three medical centers between 2019 and 2025.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ESCC post-nICT cohort | This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma (ESCC) who received at least one cycle of neoadjuvant immunochemotherapy (nICT) followed by radical esophagectomy. Patients were treated across three medical centers between 2019 and 2025. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) | Defined as the time from the date of confirmed diagnosis to the date of death from any cause or the date of last follow-up. | From date of diagnosis until the date of death from any cause, assessed up to 120 months. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The study population consists of patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who were treated across three medical centers in China (West China Hospital of Sichuan University, Mianzhu Hospital, and Suining Central Hospital) between 2019 and 2025. This real-world clinical cohort specifically comprises adult patients (aged 18 to 80 years) who received at least one cycle of neoadjuvant immunochemotherapy (nICT) prior to undergoing curative-intent radical esophagectomy.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West China Hospital, Sichuan University | Chengdu | Sichuan | 610041 | China |
Not provided
Not provided
Not provided
Not provided